nach oben

Journal of Neural Transmission

Erschienen in:

14.03.2020 | Neurology and Preclinical Neurological Studies - Review Article

Parkinson’s disease treatment: past, present, and future

verfasst von: John D. Elsworth

Erschienen in: Journal of Neural Transmission | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

The substantial contributions of Dr. Gerald Stern to past and current treatments for Parkinson’s disease patients are reviewed, which form the foundation for an evaluation of future options to control symptoms and halt progression of the disease. These opportunities will depend on a greater understanding of the relative contributions of the environment, genetic and epigenetic influences to disease onset, and promise to emerge as strategies for improving mitochondrial function, halting accumulation of synuclein and neuromelanin, in addition to refinement of stem cell and gene therapies. Such advances will be achieved through deployment of improved models for the disease.

Abbott A (2014) Fetal-cell revival for Parkinson's. Nature 510:195–196. https://doi.org/10.1038/510195a CrossRefPubMed

Aly AE, Waszczak BL (2015) Intranasal gene delivery for treating Parkinson's disease: overcoming the blood-brain barrier. Expert Opin Drug Deliv 12:1923–1941. https://doi.org/10.1517/17425247.2015.1069815 CrossRefPubMed

Barinapa M (1995) Researchers broaden the attack on Parkinson's disease. Science 267:455–456. https://doi.org/10.1126/science.7824944 CrossRefPubMed

Bjugstad KB, Teng YD, Redmond DE Jr, Elsworth JD, Roth RH, Cornelius SK, Snyder EY, Sladek JR Jr (2008) Human neural stem cells migrate along the nigrostriatal pathway in a primate model of Parkinson's disease. Exp Neurol 211:362–369. https://doi.org/10.1016/j.expneurol.2008.01.025 CrossRefPubMedPubMedCentral

Blackburn JK, Curry DW, Thomsen AN, Roth RH, Elsworth JD (2020) Pioglitazone activates paraoxonase-2 in the brain: a novel neuroprotective mechanism. Exp Neurol 327:113234. https://doi.org/10.1016/j.expneurol.2020.113234 CrossRefPubMed

Brakedal B, Flones I, Reiter SF, Torkildsen O, Dolle C, Assmus J, Haugarvoll K, Tzoulis C (2017) Glitazone use associated with reduced risk of Parkinson's disease. Mov Disord 32:1594–1599. https://doi.org/10.1002/mds.27128 CrossRefPubMedPubMedCentral

Bronstein JM, Tagliati M, Alterman RL, Lozano AM, Volkmann J, Stefani A, Horak FB, Okun MS, Foote KD, Krack P, Pahwa R, Henderson JM, Hariz MI, Bakay RA, Rezai A, Marks WJ Jr, Moro E, Vitek JL, Weaver FM, Gross RE, DeLong MR (2011) Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol 68:165. https://doi.org/10.1001/archneurol.2010.260 CrossRefPubMed

Bullich C, Keshavarzian A, Garssen J, Kraneveld A, Perez-Pardo P (2019) Gut vibes in Parkinson's disease: the microbiota-gut-brain axis. Mov Disord Clin Pract 6:639–651. https://doi.org/10.1002/mdc3.12840 CrossRefPubMed

Cai W, Yang T, Liu H, Han L, Zhang K, Hu X, Zhang X, Yin KJ, Gao Y, Bennett MVL, Leak RK, Chen J (2018) Peroxisome proliferator-activated receptor gamma (PPARgamma): a master gatekeeper in CNS injury and repair. Prog Neurobiol 163–164:27–58. https://doi.org/10.1016/j.pneurobio.2017.10.002 CrossRefPubMed

Carney BJ, Shah K (2011) Migration and fate of therapeutic stem cells in different brain disease models. Neuroscience 197:37–47. https://doi.org/10.1016/j.neuroscience.2011.08.063 CrossRefPubMedPubMedCentral

Cassell K, Shaw K, Stern G (1973) A computerised tracking technique for the assessment of Parkinsonian motor disabilities. Brain 96:815–826. https://doi.org/10.1093/brain/96.4.815 CrossRefPubMed

Chen H, Ritz B (2018) The search for environmental causes of parkinson's disease: moving forward. J Parkinsons Dis 8:S9–S17. https://doi.org/10.3233/JPD-181493 CrossRefPubMedPubMedCentral

Chen Y, Zhu G, Shi L, Liu D, Zhang X, Liu Y, Yuan T, Du T, Zhang J (2019) Establishment of a novel mesial temporal lobe epilepsy rhesus monkey model via intra-hippocampal and intra-amygdala kainic acid injection assisted by neurosurgical robot system. Brain Res Bull 149:32–41. https://doi.org/10.1016/j.brainresbull.2019.04.002 CrossRefPubMed

Chiueh CC, Markey SP, Burns RS, Johannessen JN, Pert A, Kopin IJ (1984) Neurochemical and behavioral effects of systemic and intranigral administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat. Eur J Pharmacol 100:189–194. https://doi.org/10.1016/0014-2999(84)90221-8 CrossRefPubMed

Choi-Lundberg DL, Lin Q, Chang YN, Chiang YL, Hay CM, Mohajeri H, Davidson BL, Bohn MC (1997) Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 275:838–841. https://doi.org/10.1126/science.275.5301.838 CrossRefPubMed

Christine CW, Bankiewicz KS, Van Laar AD, Richardson RM, Ravina B, Kells AP, Boot B, Martin AJ, Nutt J, Thompson ME, Larson PS (2019) Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease. Ann Neurol 85:704–714. https://doi.org/10.1002/ana.25450 CrossRefPubMedPubMedCentral

Costa LG, de Laat R, Dao K, Pellacani C, Cole TB, Furlong CE (2014) Paraoxonase-2 (PON2) in brain and its potential role in neuroprotection. Neurotoxicology 43:3–9. https://doi.org/10.1016/j.neuro.2013.08.011 CrossRefPubMed

Danielyan L, Schafer R, von Ameln-Mayerhofer A, Bernhard F, Verleysdonk S, Buadze M, Lourhmati A, Klopfer T, Schaumann F, Schmid B, Koehle C, Proksch B, Weissert R, Reichardt HM, van den Brandt J, Buniatian GH, Schwab M, Gleiter CH, Frey WH 2nd (2011) Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease. Rejuvenation Res 14:3–16. https://doi.org/10.1089/rej.2010.1130 CrossRefPubMed

De Los Angeles A, Hyun I, Latham SR, Elsworth JD, Redmond DE Jr (2019) Human-monkey chimeras for modeling human disease: opportunities and challenges. Methods Mol Biol 2005:221–231. https://doi.org/10.1007/978-1-4939-9524-0_15 CrossRefPubMed

Desikan RS, Schork AJ, Wang Y, Witoelar A, Sharma M, McEvoy LK, Holland D, Brewer JB, Chen CH, Thompson WK, Harold D, Williams J, Owen MJ, O'Donovan MC, Pericak-Vance MA, Mayeux R, Haines JL, Farrer LA, Schellenberg GD, Heutink P, Singleton AB, Brice A, Wood NW, Hardy J, Martinez M, Choi SH, DeStefano A, Ikram MA, Bis JC, Smith A, Fitzpatrick AL, Launer L, van Duijn C, Seshadri S, Ulstein ID, Aarsland D, Fladby T, Djurovic S, Hyman BT, Snaedal J, Stefansson H, Stefansson K, Gasser T, Andreassen OA, Dale AM, Adni AGC, Investigators I (2015) Genetic overlap between Alzheimer's disease and Parkinson's disease at the MAPT locus. Mol Psychiatry 20:1588–1595. https://doi.org/10.1038/mp.2015.6 CrossRefPubMedPubMedCentral

Devarajan A, Bourquard N, Hama S, Navab M, Grijalva VR, Morvardi S, Clarke CF, Vergnes L, Reue K, Teiber JF, Reddy ST (2011) Paraoxonase 2 deficiency alters mitochondrial function and exacerbates the development of atherosclerosis. Antioxid Redox Signal 14:341–351. https://doi.org/10.1089/ars.2010.3430 CrossRefPubMedPubMedCentral

Duda J, Potschke C, Liss B (2016) Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's disease. J Neurochem 139(Suppl 1):156–178. https://doi.org/10.1111/jnc.13572 CrossRefPubMedPubMedCentral

Elsworth JD, Glover V, Reynolds GP, Sandler M, Lees AJ, Phuapradit P, Shaw KM, Stern GM, Kumar P (1978) Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect'. Psychopharmacology 57:33–38. https://doi.org/10.1007/bf00426954 CrossRefPubMed

Faggiani E, Benazzouz A (2017) Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: from history to the interaction with the monoaminergic systems. Prog Neurobiol 151:139–156. https://doi.org/10.1016/j.pneurobio.2016.07.003 CrossRefPubMed

Frankel JP, Hughes A, Lees AJ, Stern GM (1990) Marijuana for parkinsonian tremor. J Neurol Neurosurg Psychiatry 53:436. https://doi.org/10.1136/jnnp.53.5.436 CrossRefPubMedPubMedCentral

Garrick JM, Dao K, de Laat R, Elsworth J, Cole TB, Marsillach J, Furlong CE, Costa LG (2016) Developmental expression of paraoxonase 2. Chem Biol Interact 259:168–174. https://doi.org/10.1016/j.cbi.2016.04.001 CrossRefPubMedPubMedCentral

Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, Trojanowski JQ, Lee VM (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300:636–640. https://doi.org/10.1126/science.1082324 CrossRefPubMed

Grenier K, Kao J, Diamandis P (2020) Three-dimensional modeling of human neurodegeneration: brain organoids coming of age. Mol Psychiatry 25:254–274. https://doi.org/10.1038/s41380-019-0500-7 CrossRefPubMed

Herrero MT, Hirsch EC, Kastner A, Ruberg M, Luquin MR, Laguna J, Javoy-Agid F, Obeso JA, Agid Y (1993) Does neuromelanin contribute to the vulnerability of catecholaminergic neurons in monkeys intoxicated with MPTP? Neuroscience 56:499–511. https://doi.org/10.1016/0306-4522(93)90349-k CrossRefPubMed

Hunter KR, Stern GM, Laurence DR, Armitage P (1970) Combined treatment of parkinsonism with l-dopa and amantadine. Lancet 2:566. https://doi.org/10.1016/s0140-6736(70)91365-6 CrossRefPubMed

Investigators NETiPDF-Z (2015) Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol 14:795–803. https://doi.org/10.1016/S1474-4422(15)00144-1 CrossRef

Jellinger KA (2011) Interaction between alpha-synuclein and other proteins in neurodegenerative disorders. Sci World J 11:1893–1907. https://doi.org/10.1100/2011/371893 CrossRef

Kaplitt MG (2019) Gene-targeting approaches for movement disorders: recent advances. Curr Opin Neurol 32:566–570. https://doi.org/10.1097/WCO.0000000000000719 CrossRefPubMed

Kirik D, Cederfjall E, Halliday G, Petersen A (2017) Gene therapy for Parkinson's disease: disease modification by GDNF family of ligands. Neurobiol Dis 97:179–188. https://doi.org/10.1016/j.nbd.2016.09.008 CrossRefPubMed

Kleedorfer B, Turjanski N, Ryan R, Lees AJ, Milroy C, Stern GM (1991) Intranasal apomorphine in Parkinson's disease. Neurology 41:761–762. https://doi.org/10.1212/wnl.41.5.761-a CrossRefPubMed

Lees AJ, Shaw KM, Kohout LJ, Stern GM, Elsworth JD, Sandler M, Youdim MB (1977) Deprenyl in Parkinson's disease. Lancet 2:791–795. https://doi.org/10.1016/s0140-6736(77)90725-5 CrossRefPubMed

Lees AJ, Shaw KM, Stern GM (1978) Baclofen in Parkinson's disease. J Neurol Neurosurg Psychiatry 41:707–708. https://doi.org/10.1136/jnnp.41.8.707 CrossRefPubMedPubMedCentral

Li YI, Wong G, Humphrey J, Raj T (2019) Prioritizing Parkinson's disease genes using population-scale transcriptomic data. Nat Commun 10:994. https://doi.org/10.1038/s41467-019-08912-9 CrossRefPubMedPubMedCentral

Liang CL, Nelson O, Yazdani U, Pasbakhsh P, German DC (2004) Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: human midbrain dopamine neurons. J Comp Neurol 473:97–106. https://doi.org/10.1002/cne.20098 CrossRefPubMed

Lindholm D, Eriksson O, Makela J, Belluardo N, Korhonen L (2012) PGC-1alpha: a master gene that is hard to master. Cell Mol Life Sci 69:2465–2468. https://doi.org/10.1007/s00018-012-1043-0 CrossRefPubMed

Lindvall O (2015) Treatment of Parkinson's disease using cell transplantation. Philos Trans R Soc Lond B Biol Sci 370:20140370. https://doi.org/10.1098/rstb.2014.0370 CrossRefPubMedPubMedCentral

Lu CH, Yang CY, Li CY, Hsieh CY, Ou HT (2018) Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study. Diabetologia 61:562–573. https://doi.org/10.1007/s00125-017-4499-5 CrossRefPubMed

Machado MMF, Bassani TB, Coppola-Segovia V, Moura ELR, Zanata SM, Andreatini R, Vital M (2019) PPAR-gamma agonist pioglitazone reduces microglial proliferation and NF-kappaB activation in the substantia nigra in the 6-hydroxydopamine model of Parkinson's disease. Pharmacol Rep 71:556–564. https://doi.org/10.1016/j.pharep.2018.11.005 CrossRefPubMed

Marotta N, Kim S, Krainc D (2020) Organoid and pluripotent stem cells in Parkinson's disease modeling: an expert view on their value to drug discovery. Expert Opin Drug Discov. https://doi.org/10.1080/17460441.2020.1703671 CrossRefPubMed

Marsden CD (1983) Neuromelanin and Parkinson's disease. J Neural Transm Suppl 19:121–141PubMed

McCaul JA, Stern GM (1974) Letter: Lithium in Parkinson's disease. Lancet 1:1117. https://doi.org/10.1016/s0140-6736(74)90602-3 CrossRefPubMed

McCaul JA, Cassell KJ, Stern GM (1974) Letter: intravenous thyrotrophin-releasing hormone in Parkinson's disease. Lancet 1:735. https://doi.org/10.1016/s0140-6736(74)92939-0 CrossRefPubMed

Morizane A, Kikuchi T, Hayashi T, Mizuma H, Takara S, Doi H, Mawatari A, Glasser MF, Shiina T, Ishigaki H, Itoh Y, Okita K, Yamasaki E, Doi D, Onoe H, Ogasawara K, Yamanaka S, Takahashi J (2017) MHC matching improves engraftment of iPSC-derived neurons in non-human primates. Nat Commun 8:385. https://doi.org/10.1038/s41467-017-00926-5 CrossRefPubMedPubMedCentral

Morrow BA, Roth RH, Redmond DE, Elsworth JD (2011) Impact of methamphetamine on dopamine neurons in primates is dependent on age: implications for development of Parkinson's disease. Neuroscience 189:277–285. https://doi.org/10.1016/j.neuroscience.2011.05.046 CrossRefPubMedPubMedCentral

Morrow BA, Roth RH, Redmond DE Jr, Diano S, Elsworth JD (2012) Susceptibility to a parkinsonian toxin varies during primate development. Exp Neurol 235:273–281. https://doi.org/10.1016/j.expneurol.2012.02.005 CrossRefPubMedPubMedCentral

Pacelli C, Giguere N, Bourque MJ, Levesque M, Slack RS, Trudeau LE (2015) Elevated mitochondrial bioenergetics and axonal arborization size are key contributors to the vulnerability of dopamine neurons. Curr Biol 25:2349–2360. https://doi.org/10.1016/j.cub.2015.07.050 CrossRefPubMed

Parmar M (2018) Towards stem cell based therapies for Parkinson's disease. Development. https://doi.org/10.1242/dev.156117 CrossRefPubMed

Parsanejad M, Bourquard N, Qu D, Zhang Y, Huang E, Rousseaux MW, Aleyasin H, Irrcher I, Callaghan S, Vaillant DC, Kim RH, Slack RS, Mak TW, Reddy ST, Figeys D, Park DS (2014) DJ-1 interacts with and regulates paraoxonase-2, an enzyme critical for neuronal survival in response to oxidative stress. PLoS ONE 9:e106601. https://doi.org/10.1371/journal.pone.0106601 CrossRefPubMedPubMedCentral

Pissadaki EK, Bolam JP (2013) The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson's disease. Front Comput Neurosci 7:13. https://doi.org/10.3389/fncom.2013.00013 CrossRefPubMedPubMedCentral

Pozo Devoto VM, Falzone TL (2017) Mitochondrial dynamics in Parkinson's disease: a role for alpha-synuclein? Dis Model Mech 10:1075–1087. https://doi.org/10.1242/dmm.026294 CrossRefPubMedPubMedCentral

Riederer P, Berg D, Casadei N, Cheng F, Classen J, Dresel C, Jost W, Kruger R, Muller T, Reichmann H, Riess O, Storch A, Strobel S, van Eimeren T, Volker HU, Winkler J, Winklhofer KF, Wullner U, Zunke F, Monoranu CM (2019) alpha-Synuclein in Parkinson's disease: causal or bystander? J Neural Transm (Vienna) 126:815–840. https://doi.org/10.1007/s00702-019-02025-9 CrossRef

Sandler M, Corne SJ, Stephens R, Shaw DM, Hunter DR, Stern GM (1972) Metatyrosine in the treatment of parkinsonism. Lancet 2:605. https://doi.org/10.1016/s0140-6736(72)92006-5 CrossRefPubMed

Scaduto CM (2016) Methods for creating transgenic primates. Lab Anim (NY) 45:291–292. https://doi.org/10.1038/laban.1068 CrossRef

Sharma A, Osato N, Liu H, Asthana S, Dakal TC, Ambrosini G, Bucher P, Schmitt I, Wullner U (2019) Common genetic variants associated with Parkinson's disease display widespread signature of epigenetic plasticity. Sci Rep 9:18464. https://doi.org/10.1038/s41598-019-54865-w CrossRefPubMedPubMedCentral

Shaw KM, Stern GM, Sandler M (1973) Melatonin and parkinsonism. Lancet 1:271. https://doi.org/10.1016/s0140-6736(73)90118-9 CrossRefPubMed

Stefanis L (2012) alpha-Synuclein in Parkinson's disease. Cold Spring Harb Perspect Med 2:a009399. https://doi.org/10.1101/cshperspect.a009399 CrossRefPubMedPubMedCentral

Stern G (1966) The effects of lesions in the substantia nigra. Brain 89:449–478. https://doi.org/10.1093/brain/89.3.449 CrossRefPubMed

Stern G (1969) Parkinsonism. Br Med J 4:541–542. https://doi.org/10.1136/bmj.4.5682.541 CrossRefPubMedPubMedCentral

Stern GM (1987) Vitamin E and Parkinson's disease. Lancet 1:508. https://doi.org/10.1016/s0140-6736(87)92120-9 CrossRefPubMed

Stern G (2012a) Genetics and the neurodegenerations: musings of a gadfly. J Parkinsons Dis 2:1–5. https://doi.org/10.3233/JPD-2012-11065 CrossRefPubMed

Stern G (2012b) The horse that wouldn't run. Pract Neurol 12:63–67. https://doi.org/10.1136/practneurol-2011-000113 CrossRefPubMed

Stibe CM, Lees AJ, Kempster PA, Stern GM (1988) Subcutaneous apomorphine in Parkinsonian on-off oscillations. Lancet 1:403–406. https://doi.org/10.1016/s0140-6736(88)91193-2 CrossRefPubMed

Surmeier DJ, Schumacker PT, Guzman JD, Ilijic E, Yang B, Zampese E (2017) Calcium and Parkinson's disease. Biochem Biophys Res Commun 483:1013–1019. https://doi.org/10.1016/j.bbrc.2016.08.168 CrossRefPubMed

Swanson CR, Joers V, Bondarenko V, Brunner K, Simmons HA, Ziegler TE, Kemnitz JW, Johnson JA, Emborg ME (2011) The PPAR-gamma agonist pioglitazone modulates inflammation and induces neuroprotection in Parkinsonian monkeys. J Neuroinflamm 8:91. https://doi.org/10.1186/1742-2094-8-91 CrossRef

Tseng CH (2018) Pioglitazone reduces dementia risk in patients with type 2 diabetes mellitus: a retrospective cohort analysis. J Clin Med. https://doi.org/10.3390/jcm7100306 CrossRefPubMedPubMedCentral

Ur Rasheed MS, Mishra AK, Singh MP (2017) Cytochrome P450 2D6 and Parkinson's disease: polymorphism metabolic role, risk and protection. Neurochem Res 42:3353–3361. https://doi.org/10.1007/s11064-017-2384-8 CrossRefPubMed

van Heesbeen HJ, Smidt MP (2019) Entanglement of genetics and epigenetics in Parkinson's disease. Front Neurosci 13:277. https://doi.org/10.3389/fnins.2019.00277 CrossRefPubMedPubMedCentral

Vila M (2019) Neuromelanin, aging, and neuronal vulnerability in Parkinson's disease. Mov Disord 34:1440–1451. https://doi.org/10.1002/mds.27776 CrossRefPubMedPubMedCentral

Wang D, Li S, Gessler DJ, Xie J, Zhong L, Li J, Tran K, Van Vliet K, Ren L, Su Q, He R, Goetzmann JE, Flotte TR, Agbandje-McKenna M, Gao G (2018) A rationally engineered capsid variant of AAV9 for systemic CNS-directed and peripheral tissue-detargeted gene delivery in neonates. Mol Ther Methods Clin Dev 9:234–246. https://doi.org/10.1016/j.omtm.2018.03.004 CrossRefPubMedPubMedCentral

Ward C, Stern GM, Pratt RT, McKenna P (1980) Electroconvulsive therapy in Parkinsonian patients with the "on-off" syndrome. J Neural Transm 49:133–135. https://doi.org/10.1007/bf01249195 CrossRefPubMed

Wolf DP, Morey R, Kang E, Ma H, Hayama T, Laurent LC, Mitalipov S (2017) Concise review: embryonic stem cells derived by somatic cell nuclear transfer: a horse in the race? Stem Cells 35:26–34. https://doi.org/10.1002/stem.2496 CrossRefPubMed

Wu HF, Kao LT, Shih JH, Kao HH, Chou YC, Li IH, Kao S (2018) Pioglitazone use and Parkinson's disease: a retrospective cohort study in Taiwan. BMJ Open 8:e023302. https://doi.org/10.1136/bmjopen-2018-023302 CrossRefPubMedPubMedCentral

Youle RJ, van der Bliek AM (2012) Mitochondrial fission, fusion, and stress. Science 337:1062–1065. https://doi.org/10.1126/science.1219855 CrossRefPubMedPubMedCentral

Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR (2004) Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5:863–873. https://doi.org/10.1038/nrn1537 CrossRefPubMed

Zhang PL, Chen Y, Zhang CH, Wang YX, Fernandez-Funez P (2018) Genetics of Parkinson's disease and related disorders. J Med Genet 55:73–80. https://doi.org/10.1136/jmedgenet-2017-105047 CrossRefPubMed

Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, Eklund AC, Zhang-James Y, Kim PD, Hauser MA, Grunblatt E, Moran LB, Mandel SA, Riederer P, Miller RM, Federoff HJ, Wullner U, Papapetropoulos S, Youdim MB, Cantuti-Castelvetri I, Young AB, Vance JM, Davis RL, Hedreen JC, Adler CH, Beach TG, Graeber MB, Middleton FA, Rochet JC, Scherzer CR, Global PDGEC (2010) PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med 2:52ra73. https://doi.org/10.1126/scitranslmed.3001059 CrossRefPubMedPubMedCentral

Zhou J, Bradford HF, Stern GM (1997) Influence of BDNF on the expression of the dopaminergic phenotype of tissue used for brain transplants. Brain Res Dev Brain Res 100:43–51. https://doi.org/10.1016/s0165-3806(97)00019-9 CrossRefPubMed

Titel: Parkinson’s disease treatment: past, present, and future
verfasst von: John D. Elsworth
Publikationsdatum: 14.03.2020
Verlag: Springer Vienna
Erschienen in: Journal of Neural Transmission / Ausgabe 5/2020
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-020-02167-1

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2020

A personal note—Gerald Stern and Yves Agid: A walk in Piazza del Popolo in Rome, sometime in 1998

Subacute administration of both methcathinone and manganese causes basal ganglia damage in mice resembling that in methcathinone abusers

Creation of a gene expression classifier for predicting Parkinson’s disease rate of progression

Neuroprotection in Parkinson’s disease: facts and hopes

Missing heritability in Parkinson’s disease: the emerging role of non-coding genetic variation